
News|Articles|February 3, 2025
Data-Driven Insights can Optimize Clinical Trial Site Selection
Author(s)PurpleLab
Clinical trials are crucial for drug development but often face delays due to poor site selection, which can lead to protocol violations, poor data quality, and increased costs. Ninety percent of clinical trials fail to meet their timelines, and issues like inadequate staffing and patient recruitment are significant challenges. Traditional site selection methods are inefficient, and the COVID-19 pandemic has further complicated the process. Data-driven insights can optimize site selection by evaluating current data on patient populations, investigators, and site capabilities.
Trending on Applied Clinical Trials Online
1
AI-Enabled Sites and the Future of Trial Planning: Q&A with Liz Beatty, Inato
2
ACT Brief: CTTI Risk Myth-Busting, Hidden ePRO Exclusion Criteria, and Patient-Centered Care Models
3
Operational Pragmatism in ePRO-heavy trials
4
ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots
5